Acknowledgments
ALS
AMYOTROPHIC LATERAL SCLEROSIS 1
The authors wish to thank the individuals who participated in the CENTAUR trial, as well as their caregivers and families; the NEALS site staff and the staff at the Coordination Center at the NCRI, Healey & AMG Center for ALS, Massachusetts General Hospital, and Barrow Neurological Institute; and The ALS Association for providing a grant to the NCRI/Massachusetts General Hospital to support the PRO‐ACT project. Nikhilesh Sanyal, PhD, and Lara Primak, MD, of PRECISIONscientia provided medical writing assistance with the development and revision of the manuscript under the direction of the authors, with financial support from Amylyx and in compliance with international Good Publication Practice guidelines.Data used in the preparation of this article were obtained from the Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) database. As such, the following organizations within the PRO‐ACT Consortium contributed to the design and implementation of the PRO‐ACT database and/or provided data: ALS Therapy Alliance; Amylyx Pharmaceuticals, Inc.; Cytokinetics, Inc.; Knopp Biosciences; Neuraltus Pharmaceuticals, Inc.; the Neurological Clinical Research Institute at Massachusetts General Hospital; the Northeast Amyotrophic Lateral Sclerosis Consortium; Novartis; Prize4Life; Regeneron Pharmaceuticals, Inc.; Sanofi; Teva Pharmaceutical Industries, Ltd.; and The ALS Association. Of these organizations, only Amylyx participated in the analysis of the data and the writing of the report.